Literature DB >> 16096130

From opioid maintenance to abstinence: a literature review.

Hege Kornør1, Helge Waal.   

Abstract

It appears that the literature on agonist maintenance therapies for opioid dependence pays more attention to outcomes during, rather than after, treatment. This review aims to (a) estimate to what extent opioid abstinence can be expected from former maintenance patients, (b) examine possible relationships between patient and treatment characteristics and abstinence rates and (c) assess the need for research in the field of abstinence-orientated maintenance treatment in general, and time-limited buprenorphine maintenance treatment in particular. Database searches supplemented by cross-references resulted in 12 studies included in the review. The studies were mostly naturalistic follow-up studies of former methadone maintenance patients, authored by US researchers in the 1970s. Buprenorphine was used in only one of the studies, and then as a transition between methadone and abstinence. There were considerable variations in definition and assessment of abstinence. Pooled abstinence rates ranged from 22% to 86%. The single factor associated most frequently with abstinence was voluntary participation in detoxification programmes with eligibility criteria ('therapeutic detoxification'). When 'therapeutic detoxification' was compared to 'non-therapeutic detoxification' the pooled abstinence rates were 48% and 22%, respectively. Abstinence-orientated maintenance therapy may be suitable for a subgroup of patients, but there is a substantial need for research updates.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16096130     DOI: 10.1080/09595230500170241

Source DB:  PubMed          Journal:  Drug Alcohol Rev        ISSN: 0959-5236


  8 in total

1.  A woman's experience of tapering from buprenorphine during pregnancy.

Authors:  Gabrielle Katrine Welle-Strand; Odd Kvamme; Andreas Andreassen; Edle Ravndal
Journal:  BMJ Case Rep       Date:  2014-12-24

2.  Opioid substitution therapy in manipur and nagaland, north-east india: operational research in action.

Authors:  Gregory Armstrong; Michelle Kermode; Charan Sharma; Biangtung Langkham; Nick Crofts
Journal:  Harm Reduct J       Date:  2010-12-01

3.  Early outcomes following low dose naltrexone enhancement of opioid detoxification.

Authors:  Paolo Mannelli; Ashwin A Patkar; Kathleen Peindl; Edward Gottheil; Li-Tzy Wu; David A Gorelick
Journal:  Am J Addict       Date:  2009 Mar-Apr

4.  Leaving buprenorphine treatment: patients' reasons for cessation of care.

Authors:  Jan Gryczynski; Shannon Gwin Mitchell; Jerome H Jaffe; Kevin E O'Grady; Yngvild K Olsen; Robert P Schwartz
Journal:  J Subst Abuse Treat       Date:  2013-10-14

5.  Methadone, buprenorphine and preferences for opioid agonist treatment: A qualitative analysis.

Authors:  Bobbi Jo H Yarborough; Scott P Stumbo; Dennis McCarty; Jennifer Mertens; Constance Weisner; Carla A Green
Journal:  Drug Alcohol Depend       Date:  2016-01-06       Impact factor: 4.492

6.  Cardiac surgery for infective endocarditis in patients with intravenous drug use.

Authors:  Oda Bratland Østerdal; Pirjo-Riitta Salminen; Stina Jordal; Haakon Sjursen; Øystein Wendelbo; Rune Haaverstad
Journal:  Interact Cardiovasc Thorac Surg       Date:  2016-01-29

7.  Prescribing Characteristics Associated With Opioid Overdose Following Buprenorphine Taper.

Authors:  Nikki Bozinoff; Siyu Men; Paul Kurdyak; Peter Selby; Tara Gomes
Journal:  JAMA Netw Open       Date:  2022-09-01

8.  Who stays in medication treatment for opioid use disorder? A national study of outpatient specialty treatment settings.

Authors:  Noa Krawczyk; Arthur Robin Williams; Brendan Saloner; Magdalena Cerdá
Journal:  J Subst Abuse Treat       Date:  2021-02-18
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.